Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Theriva Biologics, Inc. on June 20, 2025. The filing relates to the Company's capital raising activities under an existing registration statement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a securities offering event.
Material Changes and Events
- At-the-Market Offering: The Company filed a prospectus supplement to its effective Form S-3 Registration Statement (File No. 333-279077).
- Offering Size: The Company may offer and sell up to $2,534,352 of its common stock, par value $0.001 per share.
- Sales Agent: Sales will be conducted through A.G.P./Alliance Global Partners under an Amended and Restated At Market Issuance Sales Agreement.
- Compensation: The Sales Agent is entitled to a commission of up to 3.0% of the gross sales price per share sold.
- Sales Method: Sales will be made via "at the market offerings" as defined in Rule 415(a)(4). The Sales Agent is not required to sell any specific amount.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on operational outlook, or specific risk factors beyond standard securities law disclaimers. The document notes that the report does not constitute an offer to sell securities in any state where such an offer would be unlawful prior to registration.
Investor Verification Checklist
- Verify the current market price of TOVX common stock to assess the potential dilution impact of the $2,534,352 offering.
- Review the full Prospectus Supplement and the underlying Form S-3 (File No. 333-279077) for detailed use of proceeds.
- Monitor future filings to determine the actual volume of shares sold and the total commissions paid to the Sales Agent.
- Confirm the Company's current cash position in its most recent 10-Q or 10-K to understand the necessity of this capital raise.